Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Dipan Mehta bullish on NBFC sector

      Dipan Mehta Member of BSE & NSE has a bullish stance on NBFC sector.

    • Bull's Eye: Buy Glenmark, HPCL, Sintex, IndusInd Bank

      Akshata Deshmukh, Networth Stock Broking advises buying United Spirits for a target price of Rs 2,540 and Glenmark Pharma for a target price of Rs 765.

    • Buy Glenmark Pharma, PNB, TCS: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma, Punjab National Bank and Tata Consultancy Services.

    • Buy Glenmark Pharma: Kunal Saraogi

      Kunal Saraogi, CEO of Equityrush is of the view that one may buy Glenmark Pharma.

    • Buy BF Investment, Tata Global, Glenmark: Pankaj Jain

      Pankaj Jain of Sunteck Wealthmax recommends going long in Sona Koyo Steering Systems for a target of Rs 55 and Glenmark Pharma for a target of Rs 799.

    • Bull's Eye: Buy Tata Global, UPL, Glenmark, Tata Comm

      Kunal Saraogi, Equityrush advises buying UPL for a target price of Rs 380 and India Cements for a target price of Rs 125.

    • Get in Glenmark Pharma, says Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may get in to Glenmark Pharma and stay invested in it.

    • Buy Glenmark Pharma: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Glenmark Pharma at around Rs 555-560 as the stock may touch Rs 580 in the near term.

    • Glenmark Pharma may test Rs 650: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that Glenmark Pharma may test Rs 650 in next six months.

    • Top 10 stocks: Keep an eye on ICICI Bank, Infosys, DRL

      The top 10 stocks identified by the CNBC-TV18 research team to watch out for today are ICICI Bank, Infosys, Dr Reddy‘s , Glenmark, Ashok Leyland, HeroMoto Corp, Maruti, Jaiprakash Power, HCC, and Elantas Beck

    • Buy Glenmark Pharma, ITC; sell Bharti Airtel: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Glenmark Pharma and ITC.

    • Prefer Glenmark Pharma, Cipla: Deven Choksey

      Deven Choksey, MD of KR Choksey Shares & Securities prefers Glenmark Pharma and Cipla within the pharma space.

    • Buy Apollo Tyres, Tata Elxsi, Ipca Lab: Pankaj Jain

      Pankaj Jain of Sunteck Wealthmax suggests buying Glenmark Pharma for a target price of Rs 569 and Tata Elxsi for a target price of Rs 406.75.

    • Buy Glenmark, Ipca Lab, Godrej Consumer: Rakesh Gandhi

      Independent Technical Analyst, Rakesh Gandhi advises buying Godrej Consumer Products for a target price of Rs 735 and Glenmark Pharma for a target price of Rs 570.

    • Bull's Eye: Buy Ipca Labs, TVS Motor, Glenmark, Escorts

      Pankaj Jain of Sunteck Wealthmax advises buying Apollo Tyres for a target price of Rs 114.75 and Tata Elxsi for a target price of Rs 406.75.

    • Buy Glenmark Pharma, says Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may buy Glenmark Pharma.

    • Glenmark Pharma may test Rs 532: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that Glenmark Pharma may test Rs 532.

    • Super Six short term picks for January 24

      Hemen Kapadia of KR Choksey Securities suggests buying Glenmark Pharma with a target of Rs 516 and Jindal Steel & Power with a target of Rs 273.

    • Like Container Corp, Glenmark: Sandeep Bhatia

      Sandeep Bhatia, Executive Director & Head of Sales at Kotak Securities advises buying Container Corporation of India.

    • Bull's Eye: Buy Glenmark, Apollo Tyres, UPL, Infotech Ent

      Pankaj Jain of Sunteck Wealthmax advises buying Apollo Hospital for a target price of Rs 907 and Apollo Tyres for a target price of Rs 108.

    • Glenmark Pharma may move upto Rs 600: Abhishek Karande

      Abhishek Karande of SBI Capital Securities is of the view that Glenmark Pharma may move upto Rs 600.

    • Buy Glenmark Pharma; sell BoB, UPL: SP Tulsian

      According to SP Tulsian of sptulsian.com, one may go long in Glenmark Pharma with a target of Rs 546 and advises shorting Bank of Baroda with a target of Rs 642.

    • Buy BOI, Glenmark Pharma; sell Apollo Tyres: Dharmesh Kant

      Dharmesh Kant of Indianivesh Securities recommends buying Glenmark Pharma with a target of Rs 550 and advises selling Apollo Tyres with a target of Rs 85.

    • Bull's Eye: Buy Voltas, BOI, YES Bank, Glenmark Pharma

      Prakash Diwan of Altamount Capital Management recommends buying Voltas with a target of Rs 117.90 and UCO Bank with a target of Rs 79.50.

    • Bullish on Lupin, Aurobindo; cautious on Ranbaxy: Religare

      Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347